[1] SHI WH, GUO R, LI J, et al.Analysis of 144 cases of severe adverse drug reactions[J]. Evaluation and Analysis of Drug-Use in Hospitals of China(中国医院用药评价与分析), 2023, 23(7): 885-888. [2] LIU GB, WANG J.Analysis of 468 cases of new and serious adverse drug reactions[J]. Northwest Pharmaceutical Journal(西北药学杂志), 2022, 37(3): 185-189. [3] Ministry of Health of the People's Republic of China. Management measures for the reporting and monitoring of adverse drug reactions(药品不良反应报告和监测管理办法)[S/OL]. (2011-05-04) [2023-02-02]. https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/bgt/art/2023/art_eb5331517f7b4ed6b31b1bc5e816b88a.html. [4] The National Health and Family Planning Commission. Guidelines for the clinical application of antimicrobial agents(抗菌药物临床应用指导原则)[S]. (2015-08-27) [2023-02-02]. https://www.gov.cn/xinwen/2015-08/27/content_2920799.htm. [5] ZHAO LY, CUI HC, WEN L.Discussion on the working mode of rational use of proprietary Chinese medicines by hospital Chinese pharmacists in comprehensive internal medicine departments[J]. Chinese Traditional Patent Medicine(中成药), 2020, 42(6): 1673-1676. [6] LIU YJ, CHEN QP, CHA M.Exploration of the clinical application of proprietary Chinese medicines and the causes of adverse reactions in internal medicine in our hospital from 2017 to 2020[J]. Journal of Traditional Chinese Medicine Management(中医药管理杂志), 2021, 29(16): 86-88. [7] WU J, LIN XL, JIANG LJ, et al.Development status and case analysis of TCM ADR monitoring[J]. Chinese Medicinal Economics(中国药物经济学), 2014, 9(1): 22-25. [8] XU B, WU QH.Countermeasures and implementation effects of supervision of adjuvant drugs[J]. Evaluation and Analysis of Drug-Use in Hospitals of China(中国医院用药评价与分析), 2020, 20(3): 333-336. [9] PENG J, LI QD, HE RR, et al.Construction and application of comprehensive management mode for key monitoring auxiliary drugs in a hospital[J]. China Pharmaceuticals(中国药业), 2023, 32(14): 34-37. [10] SUN MR, WANG LY, QIAN CY, et al.Control practice of rational use of adjuvant drugs in our hospital[J]. Pharmacy of China(中国药房), 2018, 29(17): 2310-2314. [11] SHI YP, LI X, CUI XY, et al.Using the PDCA circulation method to improve intravenous infusion use in hospitalized patients[J]. Pharmacy in China(中国药房), 2022, 33(22): 2797-2800. [12] WANG JJ, PENG LR, WANG JP, et al.Analysis of 537 adverse drug reaction reports[J]. Northwest Journal of Pharmacy(西北药学杂志), 2022, 37(5): 153-157. [13] LIU LY, QIU L.Research on the monitoring of adverse drug reactions in drug regulatory departments under institutional reform[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2021, 38(5): 636-640. [14] YOU CY, XU XL, LI S, et al.140 cases of severe adverse drug reactions/events in a hospital[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(9): 617-621. [15] LIU CL, SU ZY, HUANG XY.Analysis of 496 new and serious adverse drug reaction reports[J]. Chinese Journal of Clinical Rational Drug Use(临床合理用药杂志), 2022, 15(2): 162-165. |